Consequently, it is tempting to propose that a subset of patients with HMA-resistant MDS could be more sensitive to the use of inhibitors of inflammation such as those targeting IRAK4 (Emavusertib) or TLR2 (Tomaralimab), both of them undergoing clinical trials in MDS (20). Here, IRAK4 is linked to myelodysplastic syndrome.